Sugi Predict

Sugi Predict / Compounds / SCHEMBL16637087

SCHEMBL16637087

SCHEMBL16637087

Cc1nc(N2CCN(C(=O)OC(C)(C)C)C(C(=O)O)C2)c2cc(Br)c(Cl)cc2n1

nearest known ligand 0.36

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 7/20 0.36
▸ NR1H3 Q13133 6/20 0.36
▸ TLR9 Q9NR96 3/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ GBA1 P04062 2/20 0.34
▸ MAP4K4 O95819 1/20 0.34
▸ SUV39H2 Q9H5I1 1/20 0.34
▸ OPRK1 P41145 1/20 0.34
▸ KRAS P01116 1/20 0.34
▸ MCL1 Q07820 1/20 0.34
▸ TLR7 Q9NYK1 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16637083 0.92 EIF2AK4 (0.39) NR1H2NR1H3TLR9L3MBTL1GBA1
SCHEMBL16636985 0.91 NR1H2 (0.47) NR1H2NR1H3TLR9L3MBTL1MAP4K4
SCHEMBL16637144 0.87 MAP4K4 (0.40) NR1H2NR1H3MAP4K4KRAS
SCHEMBL16637591 0.84 TLR9 (0.50) TLR9GBA1SUV39H2KRASTLR7
SCHEMBL16637903 0.81 KRAS (0.36) KRAS
SCHEMBL30826956 0.80 TLR9 (0.50) TLR9GBA1SUV39H2KRASTLR7
SCHEMBL22028936 0.80 TLR9 (0.50) TLR9GBA1SUV39H2KRASTLR7
SCHEMBL16636620 0.79 MAP4K4 (0.41) NR1H2NR1H3MAP4K4KRAS
SCHEMBL16636969 0.79 NR1H2 (0.47) NR1H2NR1H3MAP4K4
SCHEMBL22550952 0.79 TLR9 (0.35) NR1H2NR1H3TLR9GBA1SUV39H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2025-02-25 — — US disclosed
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-10-24 — — US disclosed
US-20240043441-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-02-08 — — US disclosed
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2024-01-23 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
US-20220242875-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2022-08-04 — — US disclosed
US-20210188869-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2021-06-24 — — US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 — — US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 — — US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 — — US disclosed
WO-2016044772-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC (US) 2016-03-24 — — WO disclosed
WO-2016044772-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC (US) 2016-03-24 — — WO disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188869-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS NR1H2 2945/4885NR1H3 3105/4885TLR9 3879/4885
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C KRAS, NRAS, HRAS NR1H2 3336/4885NR1H3 3617/4885TLR9 3734/4885
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C KRAS, NRAS, HRAS NR1H2 3409/4885NR1H3 3275/4885TLR9 4154/4885
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS NR1H2 3409/4885NR1H3 3275/4885TLR9 4154/4885
US-20150239900-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS NR1H2 2945/4885NR1H3 3105/4885TLR9 3879/4885
US-20230212183-A9 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS NR1H2 2945/4885NR1H3 3105/4885TLR9 3879/4885
US-20240043441-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS NR1H2 2945/4885NR1H3 3105/4885TLR9 3879/4885
US-20230303586-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS NR1H2 2945/4885NR1H3 3105/4885TLR9 3879/4885
US-20220242875-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS NR1H2 2945/4885NR1H3 3105/4885TLR9 3879/4885
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER KRAS, TP53, HRAS NR1H2 3475/4885NR1H3 3244/4885TLR9 3519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.